Biopharma solutions
Labcorp Plasma Focus:
A targeted liquid biopsy test for global clinical trials and CDx development
Actionable results even when tissue is unavailable
Inform cohort stratification and clinical trial enrollment with a 33-gene cell free DNA test covering FDA-approved and guideline-driven biomarkers for patients with advanced solid cancers. Powered by the PGDx elio plasma focus kit developed under design control to withstand the rigors of the FDA approval process, Labcorp Plasma Focus is now available in our global labs to empower your clinical trial and CDx development.*
Sensitive and Specific
Highly sensitive and featuring a highly curated gene panel focused on FDA-approved biomarkers
Fast
Sample collection and processing in 7-10 days when rapid results are needed†
Global availability
Standardized, efficient service leveraging Labcorp’s extensive global network
| Specification | Labcorp Plasma Focus | |
|---|---|---|
| Intended use | For Research Use Only* | |
| Featured applications | Cohort stratification, clinical trial enrollment | |
| Genes evaluated | 33 | |
| Panel size | 0.24x Mb total | |
| Accepted sample types and input quantities | Whole blood | 2 x 10 mL Streck BCT |
| Plasma | 3-5 mL recommended; 1 mL minimum (RUO only) | |
| Cell free DNA | 25 ng recommended; 10 ng minimum (RUO only) | |
| Turnaround time | 7-10 days on average+ | |
| Average total/De-duplicated coverage | 30,000x/2,600x | |
| Variants and biomarkers assessed | SNVs, indels, rearrangements, amplifications Microsatellite instability (MSI) | |
| Variant Allele Frequency (VAF) to report | 0.1% (select actionable); 0.5% (all bases) | |
| Indel detection | Up to 42 bp insertions and deletions | |
| Sample pass rate | 96% | |
| Data processing workflow | Single automated pipeline; custom analysis available | |
| Data reported | Standard trial report (customizable upon request) Supplementary files available upon request | |
*For Research Use Only. Available for Investigational Use after appropriate regulatory considerations.
†Turnaround time for prospective studies. Exploratory and retrospective TAT dependent on statement of work.
Gene list
Labcorp Plasma Focus targets 33 actionable genes for somatic SNVs and indels, amplifications in 8 genes, fusions in 5 genes, and detects microsatellite instability (MSI).
| Full coding region for 33 genes: | |||||
|---|---|---|---|---|---|
| AKT1 | no | CHH1 | MYC | yes | |
| ALK | ◇ | CSF1R | NRAS | ||
| APC | EGFR | yes | NTRK1 | ◇ | |
| ARID1AC | ERBB2 | yes | PDGFRA | ||
| ATM | EZH2 | PIK3CA | |||
| BRAF | FGFR1 | POLD1 | |||
| BRCA1 | FGFR2 | yes◇ | POLE | ||
| BRCA2 | HRAS | RAF1 | |||
| BRIP1 | KIT | yes | RET | ◇ | |
| CCND1 | yes | KRAS | ROS1 | ◇ | |
| CD274 | yes | MET | yes | TP53 | |
| ◇ | Amplifications | |||
yes | Translocations | |||
Global Biopharma Service
Now available from Labcorp owned and operated sites in Baltimore, U.S.; Geneva, Switzerland and Shanghai, China